RecruitingNCT06986486

Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma

Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy Followed by Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma: pCOLA


Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Enrollment

8 participants

Start Date

Jun 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This is multicentric, single-arm, observational, investigator-drive study investigating the efficacy of liver transplantation after successful downstaging/disease control of unresectable perihilar cholangiocarcinoma using chemotherapy +/- immunotherapy and stereotactic body radiation therapy (SBRT).


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating whether liver transplantation is a safe and effective treatment option for people with a specific type of bile duct cancer (called perihilar cholangiocarcinoma) that cannot be surgically removed. **You may be eligible if...** - You are 18–70 years old - You have been diagnosed with unresectable perihilar cholangiocarcinoma (a bile duct cancer that cannot be surgically removed), arising at least 1 cm above the upper border of the pancreas, with a tumor no larger than 3 cm - You have no spread of cancer to lymph nodes or other organs - You have had biliary stenting (a procedure to keep the bile duct open) in all liver segments - You have no other active or recent cancers (within 5 years) **You may NOT be eligible if...** - Your cancer has spread to other parts of the body - You have other cancers or contraindications to liver transplantation - You are outside the 18–70 age range Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Fondazione IRCCS Istituto Nazionale Tumori di Milano

Milan, Michigan, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06986486


Related Trials